Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00441792 · ClinicalTrials.gov registry record · NA

The Effect of Etomidate on Patient Outcomes After Single Bolus Doses

A NA study, sponsored by Advocate Hospital System.

Completed
Registry status
NA
Development phase
122
Enrollment target

NCT00441792 is a NA study that has completed, run by Advocate Hospital System. The registered enrollment target is 122 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00441792, a NA study, has completed, sponsored by Advocate Hospital System.

COMPLETED
Registry status
NA
Development phase
122 participants
Enrollment target

Study Summary

The primary aim is to determine the difference in hospital length of stay between septic patients given etomidate and those given midazolam for induction during rapid sequence intubation (RSI) in the emergency department. To achieve this aim we plan to perform a prospective randomized trial measuring the length of stay of patients meeting sepsis criteria and requiring intubation. The investigators will compare in-hospital mortality rates between patients given etomidate and patients given midazolam for induction. In addition to hospital length of stay, secondary endpoints between the two groups will include length of stay in the intensive care unit, death within 48 hours of admission, and total number of days intubated. Research Hypothesis: In adult patients presenting to the emergency department with sepsis and requiring rapid sequence intubation, the length of stay of patients given etomidate will be greater than that of patients given the alternative agent midazolam for induction.

Interventions

  • DRUG Etomidate
  • DRUG midazolam

Trial Details

FieldValue
Enrollment Target 122 participants
Start Date 2007-10
Est. Completion 2010-12
Phase NA

Sponsor

Advocate Hospital System

4 total trials

What the Registry Record Tells You About NCT00441792

The ClinicalTrials.gov registry entry for NCT00441792 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advocate Hospital System, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Etomidate is the first listed.

NCT00441792 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00441792 about?

NCT00441792 is a clinical study titled "The Effect of Etomidate on Patient Outcomes After Single Bolus Doses". The primary aim is to determine the difference in hospital length of stay between septic patients given etomidate and those given midazolam for induction during rapid sequence intubation (RSI) in the emergency department. To achieve this aim we plan to perform a prospective randomized trial measurin...

What is the current status of trial NCT00441792?

This trial is currently completed. It is a NA study. The enrollment target is 122 participants. The study started on 2007-10. Estimated completion is 2010-12.

What interventions are being tested in trial NCT00441792?

The interventions under investigation include: Etomidate (DRUG), midazolam (DRUG).

Who is sponsoring clinical trial NCT00441792?

This trial is sponsored by Advocate Hospital System, which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.